Health News

New Pharmaceutical Strategy for Europe 25-11-2020

 
Pharma_Strategy_EC_Schinas.jpg

Shaping future pharma policies for increased accessibility and affordability of medicines

On November 25 the European Commission released the new Pharmaceutical Strategy for Europe. The Strategy is intended as a roadmap for future action in the pharmaceutical sector, detailing a number of legislative and non-legislative initiatives for the coming years. Such actions should be deployed jointly with Member States.

Paving the way for ambitious EU health budget 13-11-2020

 
EU4Health.jpg

ESIP welcomes the political agreement for a reinforced EU4Health Programme

On November 10 the European Parliament and the German Presidency of the Council reached a political agreement on the next Multiannual Financial Framework (MFF 2021-2027) and recovery package. The new political package includes a budget reinforcement of EUR 15 billion. More precisely the envelope for EU4Health would be tripled compared to the budget set by the Council in July, reaching a final amount of EUR 5.1 billion. This increase was hailed by the European Parliament and Commission as a major victory. Furthermore, on November 13 the European Parliament adopted a resolution on the EU4Health programme, calling to use EU funds to increase disease prevention, foster the digital transformation of health systems, and improve crisis-preparedness with a view to mitigating shortages of medicines and medical devices. 

Towards a strong EU Health Union? 11-11-2020

 
EU_Health_Union.png

ESIP first reaction to the new EU Health Package on preparedness to cross-border threats

On November 11 the Commission released a package of three legislative proposals on Building a European Health Union: Reinforcing the EU’s resilience for cross-border health threats. The proposals are a new Regulation on serious cross-border threats to health, and two Regulations on reinforced roles for the European Medicines Agency (EMA) and for the European Centre for Disease Prevention and Control (ECDC). The three initiatives are accompanied by a Communication on Building a European Health Union.

Healthcare systems post-COVID: pressing reset? 29-10-2020

 
POLITICO_panel_2020_10_28.png

ESIP participates in a POLITICO panel on how to increase healthcare systems' sustainability

On October 28, Ilka Woelfle - ESIP's President - represented ESIP in a POLITICO panel discussion on Healthcare systems post-COVID 19: pressing reset? bringing to the table payers’ views on how to increase the sustainability of healthcare systems. The panel was also joined by representatives of healthcare professionals, patients as well as by Andrzej Rys, from the European Commission Directorate General for Health and Food Safety (DG SANTE).

Tackling Medicine Shortages beyond COVID-19 28-09-2020

 
Medicine_Shortages__1_.jpg

Actions to secure continuous supply of quality, effective and safe medicines

The ongoing COVID-19 pandemic highlighted existing shortcomings in healthcare systems across the EU: supply chains of both medicinal products and medical devices have been impacted by the crisis, increasing the risks of shortages of essential drugs and equipment and consequently causing treatment delays and disruptions. Hence, the temporary and permanent unavailability of medicines severely affects patients’ health and puts a serious strain on European healthcare systems.

Transparency in the EU's Vaccines Strategy 18-09-2020

 
COVID-19_vaccine.png

ESIP joins the Fair Pricing Coalition calling for transparent investment on COVID-19 vaccines

The COVID-19 crisis has put strains on healthcare system in Europe and across the world. In the attempt to overcome the crisis, the EU engaged in a number of measures and initiatives aimed at countering disruptions in the European health, economic and social systems. Amongst others, the COVID-19 European vaccine strategy, based on Advance Purchase Agreements (APAs), has been used for the join procurement of vaccines for COVID-19.

The future of EU Pharma beyond COVID-19 15-09-2020

 
ESIP_Reply_to_the_Public_Consultation_on_the_Pharma_Strategy__8_.jpg

ESIP responds to the Public Consultation on the EU Pharmaceutical Strategy

Ahead of the release of the Pharmaceutical Strategy for Europe, the European Social Insurance Platform (ESIP) submitted its contribution to the related Public Consultation and welcomed the Commission’s initiative to ensure equal access to safe, quality and affordable medicines, while promoting the sustainability of healthcare systems.

ESIP calls for patient-centered data spaces 31-07-2020

 
Data_website_pic.jpg

Feedback to the Commission's roadmap on Common European Data Spaces

Following the publication of the roadmap on a new 'Legislative framework for the governance of common European data spaces', ESIP released today its feedback on the creation of a Single Market for data. Among the sectoral European data spaces envisaged is one on health. ESIP overall welcomes the Commission’s initiative to increase and improve the accessibility, usability and interoperability of data – both held by public sector bodies and consented data voluntarily provided by individuals and companies. The initiative also aims at reducing the costs of data transformation and transaction.

Health is wealth: for a strong EU health policy 24-07-2020

 
EU_leaders_COVID.jpg

ESIP calls for a more ambitious EU4Health Programme

On 21 July, European leaders reached an agreement on the EU budget for the next seven years for a total amount of €1.074 billion. They also agreed on the temporary Next Generation EU instrument providing an additional €750 billion to support economic recovery which will be raised on the financial markets by the European Commission on behalf of the EU.

Building a balanced pharma strategy 07-07-2020

 
Pharmaceutical_pricing.jpg

First insights into the Pharmaceutical Strategy Roadmap

As the European Commission launches the debate on the future Pharmaceutical Strategy for Europe, ESIP provided its first insights to the published roadmap. ESIP overall welcomes the Commission’s initiative and calls for a balanced approach taking into consideration both access to innovation that responds to unmet medical need and support to the financial sustainability of health systems.